{"entity":{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","aka":[],"tldr":"New York haematologist who led MANIFEST-2, the trial testing whether adding the BET inhibitor pelabresib to ruxolitinib helps people with myelofibrosis more than ruxolitinib alone.","summary":"Raajit Rampal directs the myeloproliferative neoplasms programme at Memorial Sloan Kettering Cancer Center. He was the global lead investigator and first author of the primary report of MANIFEST-2, the phase 3 trial of pelabresib plus ruxolitinib against placebo plus ruxolitinib in JAK inhibitor-naive myelofibrosis, which met its spleen-volume primary endpoint. His research covers the genetics of progression from chronic myeloproliferative neoplasms to acute leukaemia.","asOf":"2026-09-18","links":[],"tags":["mpn","trialist"],"related":[],"cancers":["primary-myelofibrosis","myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["manifest-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-raajit-rampal-nature-2020","paper-raajit-rampal-blood-2014","paper-raajit-rampal-cancer-discov-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Myelofibrosis","Myeloproliferative neoplasms","Combination therapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rampal%5BAuthor%5D"}],"papers":[{"title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","journal":"Nature","year":2020,"url":"https://doi.org/10.1038/s41586-020-2864-x","doi":"10.1038/s41586-020-2864-x","note":"Europe PMC author record matched by affiliation (Memorial Sloan Kettering Cancer Center); 456 citations on Europe PMC."},{"title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","journal":"Blood","year":2014,"url":"https://doi.org/10.1182/blood-2014-02-554634","doi":"10.1182/blood-2014-02-554634","note":"Europe PMC author record matched by affiliation (Memorial Sloan Kettering Cancer Center); 349 citations on Europe PMC."},{"title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","journal":"Cancer Discovery","year":2015,"url":"https://doi.org/10.1158/2159-8290.cd-14-0736","doi":"10.1158/2159-8290.cd-14-0736","note":"Europe PMC author record matched by affiliation (Memorial Sloan Kettering Cancer Center); 279 citations on Europe PMC."}],"orcid":"0000-0002-0355-6368"},"route":"/people/raajit-rampal/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/"}],"paper":[{"id":"paper-raajit-rampal-blood-2014","kind":"paper","name":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","route":"/key-papers/paper-raajit-rampal-blood-2014/"},{"id":"paper-raajit-rampal-cancer-discov-2015","kind":"paper","name":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","route":"/key-papers/paper-raajit-rampal-cancer-discov-2015/"},{"id":"paper-raajit-rampal-nature-2020","kind":"paper","name":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","route":"/key-papers/paper-raajit-rampal-nature-2020/"}]}}